# Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

> **NCT00702052** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 58 (actual)

## Conditions studied

- Lymphoma, Mantle- Cell

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00702052
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-22
- **Primary completion:** 2012-04-20
- **Final completion:** 2012-04-20
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702052, "Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00702052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*